WGU D027 FINAL EXAM STUDY GUIDE 2026/2027 | Advanced Pathopharmacological Foundations | Questions & Verified Answers | Complete Guide | Pass Guaranteed - A+ Graded

Pass the WGU D027 Final Exam on your first attempt with this comprehensive study guide for Advanced Pathopharmacological Foundations featuring the latest 2026/2027 update with questions and verified answers. This A+ Graded resource is a complete comprehensive study guide covering all key advanced pathopharmacological content areas for the WGU D027 final exam including **cellular adaptation and injury (atrophy, hypertrophy, hyperplasia, metaplasia, dysplasia, cell death - necrosis vs apoptosis), inflammation and immunity (acute inflammation vascular/cellular phases, chronic inflammation, wound healing phases, fever pathogenesis, hypersensitivity reactions Type I anaphylactic IgE-mediated, Type II cytotoxic antibody-mediated, Type III immune complex-mediated, Type IV delayed cell-mediated; autoimmune disorders pathogenesis SLE, RA, Hashimoto's, Graves', MS, T1DM; primary vs secondary immunodeficiencies, HIV/AIDS pathophysiology), genetics and genomics (Mendelian inheritance - autosomal dominant, autosomal recessive, X-linked dominant/recessive, mitochondrial; chromosomal disorders - aneuploidy Down/Turner/Klinefelter, deletions, duplications, translocations; multifactorial inheritance; epigenetics - DNA methylation, histone modification, non-coding RNA; genetic testing - screening vs diagnostic, carrier testing, prenatal, preimplantation, pharmacogenomics, tumor genetics oncogenes/tumor suppressors), fluid, electrolyte, and acid-base disorders (sodium disorders - hypernatremia/hyponatremia causes pathophysiology clinical manifestations treatment; potassium disorders - hyperkalemia/hypokalemia ECG changes management; calcium disorders - hypercalcemia/hypocalcemia; magnesium/phosphate disorders; acid-base - metabolic acidosis/alkalosis, respiratory acidosis/alkalosis, mixed disorders, anion gap, delta ratio, compensation mechanisms, treatment approaches), hematologic disorders (anemias - microcytic iron deficiency, thalassemia lead poisoning; normocytic anemia of chronic disease, hemolytic AIHA/HS/Sickle cell; macrocytic B12/folate deficiency pernicious anemia; polycythemia vera, thrombocytopenia ITP/TTP/HIT, coagulopathies hemophilia A/B, von Willebrand, vitamin K deficiency, liver disease; DIC pathophysiology, leukemia - acute vs chronic, myeloid vs lymphoid; lymphoma - Hodgkin vs non-Hodgkin; multiple myeloma), cardiovascular disorders (hypertension - primary essential risk factors, secondary causes renal/endocrine/vascular; heart failure - HFrEF reduced ejection fraction vs HFpEF preserved ejection fraction, left vs right sided failure, forward vs backward failure, neurohormonal activation RAAS/SNS; coronary artery disease - atherosclerosis pathogenesis, stable angina, unstable angina, NSTEMI, STEMI, complications arrhythmias, heart failure, cardiogenic shock, papillary muscle rupture, ventricular septal defect, pericarditis, Dressler's; dyslipidemia pathophysiology, valvular heart disease stenosis/regurgitation aortic/mitral/tricuspid/pulmonic, cardiomyopathy dilated hypertrophic restrictive arrhythmogenic, dysrhythmias mechanisms automaticity/triggered activity/reentry, brady/tachy disorders atrial fibrillation/flutter, SVT, VT, VF, heart blocks first/second/third degree, bundle branch blocks, long QT syndrome, and pharmacotherapeutics - antihypertensives ACEIs/ARBs/CCBs/diuretics/beta-blockers/alpha-blockers/central agonists/direct vasodilators; lipid-lowering statins/ezetimibe/PCSK9 inhibitors/fibrates/niacin; antiplatelets aspirin/adenosine diphosphate receptor inhibitors/P2Y12 inhibitors/GP IIb/IIIa inhibitors; anticoagulants warfarin/heparin/DOAPs; antiarrhythmics Vaughan-Williams classification classes I-IV; heart failure medications diuretics/ACEIs/ARBs/beta-blockers/aldosterone antagonists/digoxin/ivabradine/hydralazine/nitrates/sacubitril-valsartan/SGLT2 inhibitors), respiratory disorders (obstructive lung diseases - COPD emphysema destruction of alveolar walls loss of elastic recoil air trapping vs chronic bronchitis mucus hypersecretion inflammation airway narrowing; asthma chronic inflammatory airway disease intermittent/persistent, acute exacerbations; bronchiectasis; restrictive lung diseases - interstitial lung disease pulmonary fibrosis sarcoidosis pneumoconiosis; neuromuscular weakness, chest wall disorders; pulmonary vascular disease - pulmonary embolism VTE pathogenesis Virchow's triad, acute vs chronic PE, massive submassive low-risk; pulmonary hypertension groups 1-5; acute respiratory distress syndrome ARDS pathophysiology exudative/proliferative/fibrotic phases, Berlin criteria mild/moderate/severe; respiratory infections pneumonia community-acquired vs hospital-acquired vs ventilator-associated; and pharmacotherapeutics - bronchodilators beta-2 agonists SABA/LABA, anticholinergics SAMA/LAMA, methylxanthines; anti-inflammatory corticosteroids inhaled/systemic, mast cell stabilizers, leukotriene modifiers, monoclonal antibodies anti-IgE/anti-IL5/anti-IL4/anti-IL13; phosphodiesterase-4 inhibitors roflumilast; mucolytics; oxygen therapy; pulmonary vasodilators prostacyclin analogues/endothelin receptor antagonists/PDE5 inhibitors; antimicrobials for respiratory infections, anticoagulation for PE hemodynamic support thrombolytics embolectomy), renal and urinary disorders (acute kidney injury AKI - prerenal intrinsic intrarenal postrenal phases initiation/maintenance/recovery; biomarkers; chronic kidney disease CKD stages 1-5 GFR albuminuria; complications anemia mineral bone disorder cardiovascular metabolic acidosis malnutrition; glomerular disorders - nephritic syndrome hematuria hypertension oliguria vs nephrotic syndrome proteinuria hypoalbuminemia edema hyperlipidemia; specific diseases post-streptococcal glomerulonephritis, IgA nephropathy, membranous nephropathy, minimal change disease, FSGS, rapidly progressive crescentic glomerulonephritis, Alport syndrome; tubulointerstitial nephritis; polycystic kidney disease; hypertensive nephrosclerosis; diabetic nephropathy; nephrolithiasis stone types calcium oxalate/phosphate, uric acid, struvite, cystine; UTIs cystitis/pyelonephritis complicated/uncomplicated; acute pyelonephritis; and pharmacotherapeutics - diuretics loop/thiazide/potassium-sparing/carbonic anhydrase inhibitors/osmotic; antihypertensives nephroprotection ACEIs/ARBs; immunosuppressants for glomerulonephritis corticosteroids/cyclophosphamide/ mycophenolate/calcineurin inhibitors; phosphate binders calcium-based/non-calcium-based; erythropoiesis-stimulating agents; iron supplementation; vitamin D analogues; uric acid lowering allopurinol/febuxostat; urinary analgesics phenazopyridine; antimicrobials for UTI/pyelonephritis), gastrointestinal disorders (upper GI - GERD pathophysiology lower esophageal sphincter dysfunction hiatal hernia delayed gastric emptying; gastritis acute erosive vs chronic atrophic H.pylori autoimmune; peptic ulcer disease DU vs GU H.pylori NSAIDs Zollinger-Ellison; lower GI - IBD Crohn's disease transmural skip lesions any site vs ulcerative colitis continuous mucosal limited to colon; IBS pathophysiology visceral hypersensitivity dysmotility brain-gut dysfunction post-infection, subtypes IBS-D/IBS-C/IBS-mixed; diverticular disease diverticulosis vs diverticulitis; colorectal cancer pathogenesis adenoma-carcinoma sequence genetics; hepatobiliary - hepatitis viral A/B/C/D/E, alcoholic, autoimmune, drug-induced; cirrhosis compensated vs decompensated, complications portal hypertension varices ascites hepatic encephalopathy hepatorenal syndrome hepatocellular carcinoma; acute liver failure; cholestatic disorders PBC, PSC; cholelithiasis cholesterol vs pigment stones; cholecystitis acute vs chronic; pancreatic disorders acute pancreatitis mild vs severe Atlanta classification, chronic pancreatitis, pancreatic cancer; malabsorption celiac disease autoimmune enteropathy gluten sensitivity; lactase deficiency; short bowel syndrome; and pharmacotherapeutics - acid suppressants PPIs/H2RAs/antacids/sucralfate/misoprostol; prokinetics; antiemetics 5HT3 antagonists/dopamine antagonists/neurokinin-1 antagonists/cannabinoids/antihistamines/anticholinergics; H.pylori eradication triple/quadruple therapy; antidiarrheals; laxatives; 5-ASA compounds mesalamine/sulfasalazine; corticosteroids systemic/budesonide; immunomodulators azathioprine/6-MP/methotrexate; biologics anti-TNF/anti-integrin/anti-IL12/23, JAK inhibitors; rifaximin; lactulose; neomycin; antibiotics for diverticulitis; ursodeoxycholic acid; pancreatic enzyme replacement; gluten-free diet counseling, vitamin/mineral supplementation), endocrine disorders (diabetes mellitus - type 1 absolute insulin deficiency autoimmune, DKA pathophysiology hyperglycemia ketosis metabolic acidosis; type 2 insulin resistance relative deficiency, HHNS pathophysiology hyperosmolar hyperglycemia severe dehydration; diabetes microvascular complications retinopathy/nephropathy/neuropathy; macrovascular accelerated atherosclerotic disease; diabetic foot ulcers Charcot foot; gestational diabetes; hypoglycemia unawareness; thyroid disorders - hypothyroidism primary/fetal Hashimoto's, secondary central, subclinical; myxedema coma; hyperthyroidism Graves' disease toxic adenoma multinodular goiter thyroiditis, thyrotoxic storm; thyroid nodules evaluation malignancy risk; adrenal disorders - primary adrenal insufficiency Addison's autoimmune TB infection, secondary adrenal insufficiency; adrenal crisis; Cushing's syndrome pituitary adenoma, adrenal tumor, ectopic ACTH, exogenous glucocorticoid excess; hyperaldosteronism primary Conn's vs secondary; pheochromocytoma paraganglioma; pituitary disorders - hypo/hyperpituitarism, prolactinoma, acromegaly, Cushing's disease, diabetes insipidus central vs nephrogenic, SIADH; calcium/bone disorders - hyperparathyroidism primary/secondary/tertiary; hypoparathyroidism; osteoporosis pathophysiology uncoupling bone resorption exceeds formation, primary age-related/postmenopausal, secondary medications malabsorption chronic disease, fragility fractures; osteomalacia rickets; Paget's disease; and pharmacotherapeutics - insulins rapid/short/intermediate/long/premixed; insulin pumps; glucose monitoring CGM; oral/injectable antidiabetics metformin/sulfonylureas/meglitinides/TZDs/DPP-4 inhibitors/GLP-1 agonists/SGLT2 inhibitors/alpha-glucosidase inhibitors/amylin analogues/bile acid sequestrants/dopamine agonists; glucagon; diabetes equipment; thyroid hormone levothyroxine/liothyronine; antithyroid drugs methimazole/propylthiouracil; radioactive iodine; beta-blockers for hyperthyroidism; glucocorticoids hydrocortisone/prednisone/prednisolone/methylprednisolone/dexamethasone; mineralocorticoids fludrocortisone; adrenal steroid synthesis inhibitors ketoconazole/metyrapone; somatostatin analogs; dopamine agonists cabergoline/bromocriptine; GH receptor antagonists pegvisomant; vasopressin analogues desmopressin; vasopressin receptor antagonists tolvaptan; bisphosphonates/denosumab/teriparatide/abaloparatide/romosozumab/calcitonin; calcium/vitamin D supplementation; cinacalcet; PTH analogues; calcimimetics), neurologic disorders (cerebrovascular - ischemic stroke thrombotic/embolic/lacunar, transient ischemic attack, acute management tPA window endovascular thrombectomy; hemorrhagic stroke intracerebral vs subarachnoid, aneurysm AVM; seizure disorders - focal aware/impaired awareness, generalized tonic-clonic/absence/myoclonic/atonic/clonic/tonic; epilepsy syndromes; status epilepticus; neurodegenerative - Alzheimer's disease amyloid plaques neurofibrillary tangles; frontotemporal dementia; Lewy body dementia dementia with Parkinsonism visual hallucinations cognitive fluctuations; Parkinson's disease substantia nigra degeneration Lewy bodies, motor symptoms bradykinesia/tremor/rigidity/postural instability, non-motor symptoms autonomic dysfunction depression dementia; Huntington's disease autosomal dominant CAG repeats chorea cognitive decline psychiatric; amyotrophic lateral sclerosis ALS upper/lower motor neuron involvement; multiple sclerosis pathophysiology demyelination plaques, relapsing-remitting, secondary progressive, primary progressive, progressive relapsing subtypes; traumatic - TBI primary vs secondary injury mechanisms, concussion, contusion, diffuse axonal injury, epidural/subdural/intraparenchymal hemorrhage, ICP management; SCI primary vs secondary injury, spinal shock, neurogenic shock, autonomic dysreflexia; infectious - meningitis bacterial vs viral vs fungal, meningococcal, pneumococcal, listeria, HSV; encephalitis viral arboviruses/HSV/enteroviruses; brain abscess; headache disorders - migraine pathophysiology cortical spreading depression, trigeminovascular activation, CGRP; tension-type; cluster; medication overuse; multiple cranial neuropathies; peripheral neuropathy; Guillain-Barré syndrome acute inflammatory demyelinating polyneuropathy; myasthenia gravis autoimmune neuromuscular junction; and pharmacotherapeutics - thrombolytics tPA, tenecteplase; antiplatelets aspirin/clopidogrel/ticagrelor/dipyridamole; anticoagulants for stroke prevention in atrial fibrillation warfarin/DOACs; antiepileptics sodium channel blockers/potassium channel openers/calcium channel blockers/GABA agonists/glutamate antagonists; specific drugs phenytoin/carbamazepine/oxcarbazepine/lamotrigine/ topiramate/zonisamide/valproate/levetiracetam/ethosuximide/gabapentin/pregabalin/tiagabine/vigabatrin; benzodiazepines for status epilepticus; Alzheimer's medications cholinesterase inhibitors donepezil/rivastigmine/galantamine; memantine NMDA antagonist; Parkinson's medications levodopa/carbidopa, COMT inhibitors entacapone/tolcapone, MAO-B inhibitors selegiline/rasagiline/safinamide, dopamine agonists pramipexole/ropinirole/rotigotine/apomorphine, amantadine, anticholinergics trihexyphenidyl/benztropine; MS disease-modifying therapies interferons/glatiramer/teriflunomide/dimethyl fumarate/fingolimod/siponimod/ozanimod/ponesimod/cladribine/natalizumab/ocrelizumab/ofatumumab/rituximab/alemtuzumab; symptomatic MS medications dalfampridine; ALS medications riluzole/edaravone; migraine acute treatment triptans/gepants/ditants/ergots/NSAIDs/antiemetics; migraine prevention beta-blockers/anticonvulsants/TCAs/SNRIs/gepants/CGRP monoclonal antibodies erenumab/galcanezumab/fremanezumab/eptinezumab; neuromuscular blockers for SCI; ICP management mannitol/hypertonic saline; corticosteroids for tumors/vasogenic edema dexamethasone; myasthenia gravis pyridostigmine/immunosuppression/intravenous immunoglobulin/plasma exchange; symptomatic neuropathic pain medications gabapentin/pregabalin/TCAs/SNRIs/topical lidocaine/capsaicin), musculoskeletal disorders (osteoarthritis - age-related cartilage degradation mechanical risk factors, Heberden's/Bouchard's nodes; rheumatoid arthritis - chronic inflammatory autoimmune synovitis pannus formation joint destruction, extra-articular manifestations rheumatoid nodules vasculitis lung heart eyes; spondyloarthropathies - ankylosing spondylitis, psoriatic arthritis, reactive arthritis, enteropathic arthritis; gout - monosodium urate crystal deposition, acute vs chronic tophaceous, pathophysiology uric acid overproduction underexcretion; pseudogout CPPD calcium pyrophosphate deposition; osteoporosis - low bone mass microarchitectural deterioration fragility fractures; osteomalacia rickets - inadequate bone mineralization vitamin D deficiency hypophosphatasia; Paget's disease of bone; septic arthritis; osteomyelitis; myopathies - muscular dystrophy Duchenne Becker, dermatomyositis polymyositis inclusion body myositis, drug-induced statins corticosteroids; fibromyalgia syndrome; and pharmacotherapeutics - osteoarthritis analgesics acetaminophen/NSAIDs/COX-2 inhibitors; intra-articular corticosteroids, hyaluronic acid viscosupplementation, topical capsaicin/NSAIDs/lidocaine; rheumatoid arthritis conventional synthetic DMARDs methotrexate/sulfasalazine/leflunomide/hydroxychloroquine, biologic DMARDs TNF inhibitors etanercept/infliximab/adalimumab/certolizumab/golimumab, IL-6 inhibitors tocilizumab/sarilumab, T-cell costimulation blocker abatacept, anti-CD20 rituximab, IL-1 inhibitors anakinra, targeted synthetic DMARDs JAK inhibitors tofacitinib/baricitinib/upadacitinib; gout acute colchicine/NSAIDs/corticosteroids, long-term urate-lowering allopurinol/febuxostat/ uricosurics probenecid/lesinurad, pegloticase; osteoporosis calcium/vitamin D, bisphosphonates alendronate/risedronate/ibandronate/zoledronic acid, denosumab, teriparatide, abaloparatide, romosozumab, calcitonin; osteomalacia vitamin D/calcium/phosphate supplementation; Paget bisphosphonates/calcitonin; musculoskeletal pain - muscle relaxants cyclobenzaprine/methocarbamol/baclofen/tizanidine, benzodiazepines, botulinum toxin; fibromyalgia pregabalin/gabapentin/TCAs/SNRIs duloxetine/milnacipran/venlafaxine, cyclobenzaprine, tramadol), reproductive disorders (female reproductive - menstrual disorders amenorrhea/oligomenorrhea/menorrhagia/metrorrhagia/dysmenorrhea/premenstrual syndrome/dysmenorrhea; PCOS pathophysiology hyperandrogenism chronic oligo-anovulation polycystic ovarian morphology metabolic syndrome infertility; endometriosis endometrial implants pelvic pain infertility; infertility evaluation/treatment; menopause perimenopause/postmenopause climacteric symptoms vasomotor genital urinary sleep mood cardiovascular bone health; hormone replacement therapy risks/benefits; pelvic organ prolapse; urinary incontinence stress/urge/mixed; male reproductive - erectile dysfunction vasculogenic neurogenic hormonal psychogenic; BPH pathophysiology stromal-glandular hyperplasia bladder outlet obstruction LUTS; prostate cancer; testicular disorders hypogonadism orchitis epididymitis testicular torsion varicocele hydrocele; male infertility; sexual dysfunction; reproductive cancers - breast cancer HER2 ER PR subtypes, cervical cancer HPV associated, ovarian cancer, endometrial cancer, vulvar/vaginal cancer, testicular, penile; STIs - bacterial chlamydia/gonorrhea/syphilis/chancroid/mycoplasma, viral HPV/HSV/HBV/HIV, parasitic trichomoniasis; and pharmacotherapeutics - hormonal contraceptives OCPs, patch, ring, injection, implant, IUD; emergency contraception; fertility medications clomiphene/letrozole/gonadotropins/GnRH analogues/metformin; hormone replacement estrogen/progesterone; SERMs tamoxifen/raloxifene; ovulation inducers; androgen therapy; phosphodiesterase-5 inhibitors sildenafil/tadalafil/vardenafil/avanafil for ED; alpha-blockers terazosin/doxazosin/tamsulosin/alfuzosin/silodosin for BPH; 5-alpha-reductase inhibitors finasteride/dutasteride for BPH; anticholinergics for overactive bladder; antispasmodics; antimicrobials for STIs ceftriaxone/azithromycin/doxycycline/benzathine penicillin/acyclovir/valacyclovir/metronidazole; antiretroviral therapy for HIV, HPV vaccine; immunosuppression for autoimmune reproductive disorders), oncologic disorders (carcinogenesis - initiation promotion progression; genetic and epigenetic mechanisms; oncogenes and tumor suppressor genes; cancer biology hallmarks; common malignancies - breast, lung non-small cell/small cell, colorectal adenocarcinoma, prostate adenocarcinoma, gastric, pancreatic, hepatocellular, esophageal, head and neck, cervical squamous/adenocarcinoma, endometrial, ovarian, renal cell, bladder transitional cell, melanoma, brain tumors glioblastoma/astrocytoma, leukemia AML/ALL/CML/CLL, lymphoma Hodgkin/non-Hodgkin, plasma cell myeloma; paraneoplastic syndromes; emergency oncologic conditions - tumor lysis syndrome, febrile neutropenia, hypercalcemia of malignancy, spinal cord compression, SVC syndrome; and pharmacotherapeutics - chemotherapy alkylating agents/antimetabolites/antitumor antibiotics/microtubule inhibitors/topoisomerase inhibitors/platinum agents/kinase inhibitors; targeted therapy small molecule inhibitors, monoclonal antibodies; immunotherapy checkpoint inhibitors, CAR-T cells, cancer vaccines; hormonal therapy for hormone-sensitive cancers; radiation therapy; supportive care antiemetics/growth factors/erythropoiesis-stimulating agents/bisphosphonates/opioid analgesics), infectious disease disorders (microbiology - bacteria classification gram-positive/negative, aerobes/anaerobes, atypical; viruses DNA/RNA; fungi yeasts/molds/dimorphic; parasites protozoa/helminths; host-pathogen interactions; antimicrobial resistance mechanisms; specific infections - respiratory community-acquired pneumonia, hospital-acquired pneumonia, ventilator-associated pneumonia, tuberculosis, pertussis, legionella, URI, pharyngitis, sinusitis, otitis media; cardiac infective endocarditis acute/subacute; vascular septic thrombophlebitis; GI infectious diarrhea bacterial C.diff/Salmonella/Shigella/Campylobacter/E.coli, viral rotavirus/norovirus, parasitic Giardia/Cryptosporidium; intra-abdominal infections; CNS meningitis meningococcal/pneumococcal/listeria/neonatal Group B strep/E.coli, encephalitis HSV/West Nile; GU UTI cystitis/pyelonephritis, prostatitis; STIs as above; skin/soft tissue cellulitis/erysipelas/necrotizing fasciitis; osteomyelitis; septic arthritis; sepsis pathophysiology dysregulated host response to infection, septic shock; antimicrobial stewardship principles; and pharmacotherapeutics - antibiotics cell wall inhibitors penicillins/cephalosporins/carbapenems/monobactams/glycopeptides/bacitracin, protein synthesis inhibitors macrolides/aminoglycosides/tetracyclines/chloramphenicol/oxazolidinones (linezolid, tedizolid)/pleuromutilins, folate synthesis inhibitors sulfonamides/trimethoprim, quinolones/DNA topoisomerase inhibitors, rifamycins, nitroimidazoles metronidazole, lipopeptides daptomycin, polymyxins colistin, fosfomycin; antivirals anti-HSV/CMV acyclovir family, anti-HIV NRTIs/NNRTIs/PIs/INSTIs/entry inhibitors, anti-HCV direct-acting antivirals, anti-influenza neuraminidase inhibitors/PA endonuclease inhibitors, anti-COVID remdesivir/paxlovid, anti-HBV entecavir/tenofovir; antifungals polyenes amphotericin B, azoles fluconazole/voriconazole/posaconazole/ isavuconazole, echinocandins caspofungin/micafungin/anidulafungin, flucytosine, terbinafine; antiparasitics anti-malarial chloroquine/artemisinin/mefloquine/atovaquone-proguanil, anti-protozoal metronidazole/tinidazole/nitazoxanide, anti-helminthic albendazole/mebendazole/ivermectin/praziquantel; antimicrobial stewardship - de-escalation, duration optimization, therapeutic drug monitoring, resistance surveillance). Each answer includes clear clinical rationales to reinforce advanced pathopharmacological reasoning. Perfect for WGU nursing students preparing for the D027 final exam. With our Pass Guarantee, you can confidently master Advanced Pathopharmacological Foundations. Download your complete WGU D027 Final Exam Comprehensive Study Guide 2026/2027 instantly!